FIELD: chemistry.
SUBSTANCE: invention relates to new pyrimidine derivatives with general formula (I), their tautomeric or stereoisomeric form, in free form, in form of pharmaceutically acceptable salt or C1-6alkyl ester which are effective antagonists of CRTH2 (G-protein-associated chemoattractant receptor, ex prone on Th2 cells) and can be used for preventing and treating diseases related to CRTH2 activity, particularly in treatment of allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, diseases related to eosinophil. In formula (I) R1 is hydrogen, or in which n is an integer from 0 to 6; -Q1- is -NH-, -N(C1-6alkyl)- or -O; Y is hydrogen, C1-6alkyl, C3-6cycloalkyl, optionally substituted with C1-6alkyl, C3-6cycloalkyl, condensed with a benzene ring, phenyl, naphthyl or 5-6-member heteroaryl, possibly condensed with a benzene ring, and containing at least one heteroatom, chosen from a group consisting of oxygen and nitrogen, where the said phenyl, naphthyl or heteroaryl are optionally substituted on the displaceable position with one or several substitutes, chosen from a group consisting of cyano, halogen, nitro, guanidine, pyrroyl, sulfamoyl, phenyloxy, phenyl, di(C1-6)alkylamino, C1-6alkanoylamino, C1-6alkyl, optionally mono-, di- or tri-substituted with halogen, C1-6alkoxy, optionally mono-, di- or tri-substituted with halogen and C1-6alkylthio, optionally mono-, di- or tri-substituted with halogen; or phenyl, condensed with 1,3-dioxolane; R2 is hydrogen or C1-6alkyl; R3 is a halogen, C1-6alkoxy, optionally mono-, di- or tri-substituted with halogen, or , R3a and R3b are independently C3-8cycloalkyl or C1-6alkyl, this C1-6alkyl is optionally substituted with hydroxyl, carboxy, C3-6cycloalkylcarbamoyl, C5-6heterocyclocarbonyl containing a heteroatom in form of nitrogen, or C1-6alkoxy, q is an integer from 1 to 3; R3c is hydrogen, hydroxyl or carboxy; Xa is -O-; R4 is hydrogen, halogen, di(C1-6alkyl) amino or C1-6alkyl, optionally substituted C1-6alkoxy or mono- , di- or tri-substituted with halogen; R5 is hydrogen or C1-6alkyl; and R6 is carboxy, carboxamide, nitrile or tetrazolyl.
EFFECT: wider field of use of compounds.
32 cl, 9 tbl, 13 ex
Title | Year | Author | Number |
---|---|---|---|
ANTITUMOR EFFECT STRENGTHENING AGENT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | 2018 |
|
RU2799006C2 |
NOVEL PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND OR SALT THEREOF | 2016 |
|
RU2705579C2 |
DERIVATIVES OF IMIDAZO[1,2-C]PYRIMIDINYL ACETIC ACID | 2005 |
|
RU2373208C2 |
CONDENSED DERIVATIVES OF AZOLPYRIMINE WITH INHIBITING PROPERTIES OF PHOSPHATIDYL INOSITOL-3-KINASE (PI3K) | 2003 |
|
RU2326881C9 |
COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | 2005 |
|
RU2401265C2 |
2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS LEUCINE-RICH REPEAT KINASE 2 (LRRK2) MODULATORS FOR TREATMENT OF PARKINSON'S DISEASE | 2012 |
|
RU2661197C2 |
COMPOUNDS AND COMPOSITIONS AS PROTEIN TYROSINE KINASE INHIBITORS | 2006 |
|
RU2386630C2 |
PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | 2007 |
|
RU2485115C2 |
NOVEL MALONIC ACID SULPHONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 2008 |
|
RU2462454C2 |
METHOD FOR PREPARING DIHYDROINDENAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND USING THEM AS PROTEIN KINASE INHIBITOR | 2009 |
|
RU2528408C2 |
Authors
Dates
2009-07-20—Published
2004-04-14—Filed